Bullish Stocks Trading Above 50Days Moving Average: $CRNC $BYSI $MDRX

The Market Signal was created as a platform to help investors, if you own (NASDAQ:CRNC), (NASDAQ:BYSI) or (NASDAQ:MDRX) and want to join the fastest growing community of investors on the web then sign up to the link below. Members get free access to the best investment tools in the world. Start trading like a pro today. This is a limited time offer so click the link below NOW.

https://themarketsignal.com/Free-Report/NOW

(Click link above or copy, paste and hit enter in your browser for your report)

Cerence Introduces Neural TTS Innovation Cerence Reader For Reading News In Cars

https://themarketsignal.com/Free-Report/CRNC

(Click link above or copy, paste and hit enter in your browser for your report)

Cerence Inc. (NASDAQ:CRNC) is currently trading 12.84% above its 50 Days simple moving average and the stock looks bullish. The company has introduced Cerence Readers which is a breathtaking human-like virtual newscaster for cars. The Cerrence Reader is based on the novel Neural TTS Innovations and it can predict and adjust tone as well as reading style for expression. The innovation brings a naturally expressive voice to drivers by reading news on the go. Most importantly the Cerence Readers can be adopted for other scenarios besides news like language learning, reading audiobooks, and many more.

Jan Dusik, Audi's Head of Development Speech Output stated that Cerence Readers is an innovative introduction that will empower the next generation of cars to interact with drivers.

Beyondspring Receives Breakthrough Therapy Designation From The FDA For Plinabulin

https://themarketsignal.com/Free-Report/BYSI

(Click link above or copy, paste and hit enter in your browser for your report)

Beyondspring Inc. (NASDAQ:BYSI) is also looking bullish and it is currently trading 11.79% above its 50 Days simple moving average. The company has received Breakthrough Therapy Designation from the US FDA and China's Centre for Drug Evaluation of the National Medical Products Administration for its lead product Plinabulin for chemotherapy-induced neutropenia indication. The BTD will expedite the development and review of Plinabulin which has from clinical evidence demonstrates that it can offer significant improvement over current therapies on various clinically significant endpoints.

The company has announced the appointment of Dr. Ravindra Majeti the Standford University Chief of Hematology to the company's Board of Directors. Majeti is the founder of Forty Seven Inc. which was acquired in March 2020 by Gilead for $4.9 billion.

Allscripts Collaborates With Sheba Medical Centres On AI Healthcare Technologies

https://themarketsignal.com/Free-Report/MDRX

(Click link above or copy, paste and hit enter in your browser for your report)

Also, another bullish looking stock is Allscripts Healthcare Solutions Inc. (NASDAQ:MDRX) which is currently trading 11.49% above its 50 Days simple moving average. Recently the company collaborated with Israeli-based Sheba Medical Centre to expedite the rate of AI technologies and boost care of patients via the hospital's ARC Innovation Centre. ARC which stands for accelerate, redesign, and collaborate, is the innovation division of Sheba Medial Centre with a vision of transforming Healthcare by 2030. The hospital uses the Allscripts dbMotion Solution to enhanced interoperability and harmonization of patient data.

Also, the company recently received five patents underscoring its commitment towards delivery of the innovative solution to customers. The move affirms the company's significant progress in health IT Innovation.

Please email or contact us for any edits or errors relating to this stock market news.

If you would like information on using our press release distribution service aimed at helping investors with the best stocks to buy and how to create your own stock portfolio. We cover the US Stock Market, Canadian Stock Market, the Australian Stock Market and other Stock Market news.

We will get back to you within 24 hours.

Disclaimer

comtex tracking

COMTEX_371120147/2705/2020-09-11T06:13:28

Is there a problem with this press release? Contact the source provider Comtex at editorialpr@comtex.com.